Kazakhstan vs OECD members: Prevalence of hypertension, female
Kazakhstan
42.5%
in 2019
OECD members
27.6%
in 2019
Kazakhstan rank
43rd
OECD members rank
40th
Prevalence of hypertension, female over time
- Kazakhstan
- OECD members
How they compare
Kazakhstan currently reports 42.5% against 27.6% in OECD members, a difference of 14.9%.
That makes Kazakhstan's figure about 1.5 times OECD members's.
Across all 30 years both countries report, Kazakhstan has been ahead every year.
Kazakhstan ranks 43rd and OECD members ranks 40th of 192 countries.
Kazakhstan has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Kazakhstan | OECD members | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 40.3% | 33.2% | 7.1% | Kazakhstan |
| 2000s | 41.8% | 31.0% | 10.8% | Kazakhstan |
| 2010s | 42.8% | 28.8% | 14.0% | Kazakhstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hypertension, female, Kazakhstan or OECD members?
- Kazakhstan, at 42.5% against 27.6% in OECD members as of 2019.
- What is the difference in prevalence of hypertension, female between Kazakhstan and OECD members?
- 14.9%, with Kazakhstan ahead.
- How many years of comparable data are there for Kazakhstan and OECD members?
- 30 years are reported by both, from 1990 to 2019.
- How do Kazakhstan and OECD members rank globally for prevalence of hypertension, female?
- Kazakhstan ranks 43rd and OECD members ranks 40th of 192 countries.
- Where does this data come from?
- World Health Organization's Global Health Observatory Data Repository, published as Prevalence of hypertension, female (% of female adults ages 30-79). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Prevalence of hypertension, female, is the percentage of female adults ages 30-79 with hypertension (defined as having systolic blood pressure =140 mmHg, diastolic blood pressure =90 mmHg, or taking medication for hypertension). The data is age-standardized.